Navigation Links
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
Date:5/19/2009

p>

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that pixantrone could cause cumulative heart damage, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q, and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room


    Investors Contact:

    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
3. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
4. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
5. Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
8. Tanning and Excessive Sun Exposure Can Cause Severe Damage to Eyes
9. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
10. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 The following is an ... Directors of China Cord Blood Corp (NYSE: CO ) ... committee of the independent directors of China Cord Blood Corp ... offer of $6.40 per share from Golden Meditech Holdings Co ... per share would greatly benefit Golden Med and Mr. Kam, ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... today announced the closing of its previously announced ... common stock at a public offering price of ... full by the underwriters of their option to ...
(Date:4/30/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... services provider, today announced that its board of directors ... 29, 2015, from a consortium (the "Consortium") led by ... and chief executive officer of the Company, and Ally ... (the "Transaction") involving the acquisition of all outstanding shares ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health science ... SureClinical’s executive team as Chief Financial Officer. ... with over 25 years in leadership roles ranging from ... Morris joins SureClinical from Marrone Bio Innovations (MBI), a ... MBI from its founding in 2006 until 2011, when ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Julie I. Morris Joins SureClinical as Chief Financial Officer 2
... Fla., Feb. 16, 2012   GeneLink Biosciences, ... company, has completed the sale of the stock ... Sciences, Inc. (GeneWize)  to Capsalus Corp. (OTCBB: WELL), ... wellness marketplace.  As previously disclosed, GeneLink and Capsalus ...
... 2012 /PRNewswire-iReach/ -- FirstMark today announced the ... cardiovascular blood test PREvent. These clinical results demonstrate the ... (2-3 years) risk of myocardial infarction and death in ... The clinical study and final data was well received ...
... today the publication of key results relating to its ... high-value G-protein-coupled receptor (GPCR) targets in Science . ... Lipid G Protein-Coupled Receptor," was co-authored by Receptos in ... Raymond Stevens, Ph.D. Drs. Rosen and Stevens are both ...
Cached Biology Technology:GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2FirstMark's Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 2Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 3Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science 4
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... EAC standard by providing ... single platform, DALLAS, Sept. 10 As ePassport ... many seek a method,to deploy border security capabilities in ... ENTU ) and 3M (NYSE: MMM ),announce a ...
... has been awarded $1 million from the US Department ... biomass conversion technologies. The grant is one of six ... develop their advanced biofuels projects. In total, the DOE ... projects for their research into how non-food feedstocks can ...
... of California White Mountain Research Station, U.S. Forest ... Integrated Climate Research in Western Mountains will host ... Tri-Valley Fairgrounds in Bishop. The conference is entitled ... will bring together distinguished researchers from a variety ...
Cached Biology News:Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 2Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 3Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 4Stevens awarded $1M for advanced biofuels research 2
... Collection of Cell Cultures (ECACC) has been ... academia and government institutes for over seven ... designed to introduce candidates to cell culture ... on more specialist areas such as planning ...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
...
Biology Products: